Navigation Links
Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial

. -- Modified intent-to-treat radiographic success rate -- cethromycin 88.3% (227/257) compared to Biaxin(R) 91.7% (232/253) [-8.8, +2.0] (p=0.2383). Based on the 91.7% clinical cure rate for Biaxin(R) being 90% or greater, a delta value of 10% or less on the lower bound and greater than zero on the upper bound [-8.8, +2.0] establishes non-inferiority. Under this analysis, the study met the endpoint of modified intent-to-treat radiographic success rate. Since p>0.05, there is not a statistically significant difference between cethromycin and Biaxin(R), which supports non-inferiority. -- Bacteriological cure rate -- cethromycin 89.1% (57/64) compared to Biaxin(R) 96.8% (61/63). The bacteriologically evaluable population for each arm of the trial was not powered to demonstrate statistical non-inferiority at a 95% confidence interval. -- Percent of bacteriologically evaluable patients -- approximately 28% of subjects in the per protocol population were bacteriologically evaluable. The Company believes that this percentage of bacteriologically evaluable patients is in-line with rates observed in precedent successful antibiotic drug approvals and will add to its overall bacteriologically evaluable patient database. -- Discontinuation rate -- from the modified intent-to-treat population, discontinuation rate due to adverse events was 1.6% for cethromycin and 2.8% for Biaxin(R). Total discontinuation rate (due to adverse events, clinical failure, exclusion criteria and withdrawal of consent) was 7.0% for cethromycin and 7.9% for Biaxin(R). Both cethromycin and Biaxin(R) were well tolerated with discontinuation rates similar to those observed in prior clinical trials.

Cethromycin was evaluated using a 300 mg once-daily dosing regimen compared to 250 mg twice-daily
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
(Date:12/17/2014)... , Dec. 17, 2014  Beamz Interactive, Inc. ... music products, today announced that it has signed ... manufacturer and supplier of innovative prosthetic, orthotic and ... part of the agreement, RSL Steeper will promote ... specifically configured for use within UK residential care ...
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
Breaking Medicine Technology:ZEISS Asserts its Position in Difficult Environment 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... 1 Orexigen® Therapeutics, Inc. (Nasdaq: OREX ... obesity, today announced that the U.S. Food and Drug ... Drug Application (NDA) for Contrave® (naltrexone SR/bupropion SR), its ... is based on a substantial body of evidence gathered ...
... , IRVINE, Calif. , June 1 Cardiogenesis ... present at the Noble Financial Sixth Annual Equity Conference - ONTRACK ... Hollywood, Florida .  Executive Chairman Paul J. McCormick will ... at 5:00 pm Eastern Time ( 2:00 pm ...
Cached Medicine Technology:Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 2Orexigen® Therapeutics Announces FDA Acceptance of Contrave® New Drug Application for the Treatment of Obesity 3Cardiogenesis Corporation to Present at Noble Financial - ONTRACK 2010 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... Hospital is the only pediatric hospital in the ... The American Nurses,Credentialing Center (ANCC) has awarded DMC ... nursing. Recognized as one of the,highest distinctions a ... five,percent of all U.S. hospitals have achieved this ...
... April 17 The Connecticut,Hospice, Inc., the nation,s ... from its first class of The Norma F. ... by a,generous grant merited by the Connecticut Hospice,s ... for education and,training in hospice and palliative care. ...
... explain antidepressants, effectiveness , , THURSDAY, April 17 (HealthDay News) ... old brain cells to their more plastic youthful condition ... only provides a possible new explanation for the antidepressant ... prospect that it could be used to treat other ...
... drinkers and heavy,smokers develop Alzheimer,s disease years earlier ... smoke heavily, according to research that,will be presented ... Meeting in Chicago, April 12-19, 2008., "These ... we can,reduce or eliminate heavy smoking and drinking, ...
... N.Y., April 17 CTG (Nasdaq: CTGX ),an ... that it would release its 2008 first quarter,financial results ... company,will hold a conference call to discuss its financial ... 10:00 a.m. Eastern Time. CTG,Chairman and Chief Executive Officer ...
... Calif., April 17 The National Center for,Autism ... for autism research, education and family support,services has ... are,flocking to NCARE resulting from the announcement to ... that families desperately need centralized,autism resources., Soonhee ...
Cached Medicine News:Health News:Children's Hospital of Michigan Awarded Prestigious Magnet Status 2Health News:The Norma F. Pfriem International Fellowship in Hospice and Palliative Care Nursing 2Health News:Prozac Makes Old Brain Cells Young 2Health News:Prozac Makes Old Brain Cells Young 3Health News:Alzheimer's Starts Earlier for Heavy Drinkers, Smokers 2Health News:CTG Announces 2008 First Quarter Conference Call and Webcast Information 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2
... and value!, Comfortable feel and ... contoured handle , Finer control while ... action , Completely autoclavable for easy ... for recalibration , Easy-to-read precision micrometer ...
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
250L...
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Medicine Products: